Physician Assistant Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Heather Roan

Physician Assistant, Medical Bossier City, LA Physician Assistant

NPI 1558819532 CMS profile 10682695

2449 Hospital Dr Ste 400, Bossier City, LA 71111

Open in the dashboard

General payments

$11,357

530 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Heather Roan of Bossier City, LA is reported in the CMS Open Payments database as having received $11,357 across 530 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Physician Assistant, Medical profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,146 103
2024 General $2,974 106
2023 General $1,563 80
2022 General $2,632 111
2021 General $2,041 130

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Heather Roan
  • Physician Assistant, Medical median
  • Middle half of Physician Assistant, Medical
  • National median

In program year 2025, general payments to Heather Roan were reported at $2,146. Among 16,675 Physician Assistant, Medical profiles paid that year, the median was $214 and the middle half received between $62 and $755.

Show as a table
Year Heather Roan Physician Assistant, Medical median Middle half National median
2019 $0 $61 $19–$193 $163
2020 $0 $20 $14–$64 $114
2021 $2,041 $156 $41–$563 $132
2022 $2,632 $185 $55–$649 $149
2023 $1,563 $199 $58–$717 $160
2024 $2,974 $206 $62–$740 $164
2025 $2,146 $214 $62–$755 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Medtronic, Inc. $2,855 63 payments
  2. Novo Nordisk Inc $921 53 payments
  3. Lilly USA, LLC $856 50 payments
  4. Corcept Therapeutics $679 44 payments
  5. Insulet Corporation $618 24 payments
  6. Dexcom, Inc. $589 29 payments
  7. Sanofi-Aventis U.S. LLC $441 28 payments
  8. Tandem Diabetes Care, Inc. $426 16 payments
  9. Xeris Pharmaceuticals, Inc. $383 23 payments
  10. AbbVie, Inc. $380 23 payments
  11. Other $3,210 177 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $10,241 523 payments
  2. Travel and Lodging $1,087 5 payments
  3. Education $29 2 payments
Products named General payments · program years 2021–2025
  1. MINIMED 780G $1,847 31 payments
  2. Korlym $679 44 payments
  3. INPEN SMART INSULIN DELIVERY SYSTEM $668 11 payments
  4. Omnipod $618 24 payments
  5. RYBELSUS $550 30 payments
  6. Dexcom G6 Transmitter $547 27 payments
  7. MOUNJARO $501 27 payments
  8. Ozempic $493 37 payments
  9. t:slim X2 Insulin Pump with Control-IQ $426 16 payments
  10. SYNTHROID $253 15 payments
  11. Other $6,488 375 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 11 drugs

Part D claims

386

Median for Physician Assistant: 241

Drug cost

$151,078

Median for Physician Assistant: $4,110

Branded share of claims

53.1%

Median for Physician Assistant: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mounjaro Tirzepatide Brand 64 $99,702
Ozempic Semaglutide Brand 18 $18,664
Omnipod 5 Dexg7g6 Pods (Gen 5) Insulin Pump Cart,auto,bt,g6/7 Brand 14 $13,379
Novolog Insulin Aspart Brand 14 $6,169
Vascepa Icosapent Ethyl Brand 12 $4,392
Icosapent Ethyl Generic 14 $3,956
Synthroid Levothyroxine Sodium Brand 61 $3,436
Levothyroxine Sodium Generic 99 $684
Methimazole Generic 53 $281
Metformin Hcl Generic 15 $232

The 10 drugs with the highest cost, of 11 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 114,276 Part D prescribers listed as Physician Assistant; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 11 billing codes

Paid by Medicare

$30,004

Medicare's payments for the services billed

Medicare patients

199

Average age 73

Services billed

607

150 women, 49 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Diabetes 53%
Arthritis 52%
Ischemic heart disease 34%
Chronic kidney disease 32%
Depression 25%
Osteoporosis 22%
Atrial fibrillation 18%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 23 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
TZIELD
  • SANOFI-AVENTIS U.S. LLC $128
$128 — —
MOUNJARO
  • Lilly USA, LLC $103
$103 64 —
TEPEZZA
  • Amgen Inc. $102
$102 — —
Korlym
  • Corcept Therapeutics $91
$91 — —
GVOKE HYPOPEN
  • Xeris Pharmaceuticals, Inc. $91
$91 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 23 in the dashboard with a free account

Records

530 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Physician Assistant, Medical in Louisiana

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record